April 1, 2022
Hello Community Partners!
Below is this week’s update around COVID vaccinations. We hope you are doing well and staying safe!
All information is based on CDC, FDA, and CDPHE (State of Colorado) guidance.
UPDATE!
On April 1, 2022, The Centers for Disease Control and Prevention has issued updated guidance for who can get a second booster dose of an mRNA COVID-19 vaccine.
The guidance includes the following groups who received their first booster dose at least 4 months ago:
-People 50 and older
-People 12 and older who are moderately to severely immunocompromised
-People 18 to 49 who received the Johnson & Johnson COVID-19 vaccine and first booster dose
If you are interested in scheduling a clinic at your community, please follow this link: 2nd COVID Booster Clinic (General Interest)
If you have specific COVID-19 questions, please email us at mobrien@gooddaypharmacy.com and she will get your question to the right person.
Thank you,
Vicki Einhellig, RPh
President & CEO
Good Day Pharmacy UPDATE on COVID-19 Vaccine Information for LTC Residents & Staff
February 18, 2022
Hello Community Partners!
Below is this week’s update around COVID vaccinations. We hope you are doing well and staying safe!
All information is based on CDC, FDA, and CDPHE (State of Colorado) guidance.
UPDATE!
- The U.S. Food and Drug Administration (FDA) granted full approval of the Moderna COVID-19 vaccine under the trade name Spikevax on January 31, 2022.
- On February 11, 2022, CDC revised the interim clinical considerations for use of COVID-19 vaccines to include an additional primary dose for individuals with moderate to severe immunocompromise
who received the Johnson & Johnson (J&J) COVID-19 vaccine. The additional primary dose should be an mRNA (Pfizer or Moderna) COVID-19 vaccine given four weeks after the first dose. People with moderate to severe immunocompromise who received a primary J&J COVID-19 vaccine should receive a total of three vaccine doses.
●On February 11, 2022, CDC revised the interim clinical considerations for use of COVID-19 vaccine booster doses in individuals with moderate to severe immunocompromise who received a primary mRNA (Pfizer or Moderna) COVID-19 vaccine; individuals with moderate to severe immunocompromise should receive a booster dose three months after completion of an mRNA (Pfizer or Moderna) COVID-19 vaccine primary series. The booster dose interval for individuals with moderate to severe immunocompromise who received a J&J COVID-19 vaccine primary series has not changed and is still two months.
On February 11, 2022, CDC removed the recommendation to delay vaccination after receiving antibody products (anti-SARS-CoV-2 monoclonal antibody therapy or convalescent plasma) as part of COVID-19 treatment. COVID-19 vaccination does not need to be delayed following receipt of monoclonal antibodies or convalescent plasma.
●On February 11, 2022, CDC updated the guidelines for booster doses for people who received a COVID-19 vaccine outside of the United States and added myocarditis or pericarditis after an mRNA COVID-19 vaccine to the precautions for COVID-19 vaccines
If you have specific COVID-19 questions, please email us at mobrien@gooddaypharmacy.com and she will get your question to the right person.
Thank you,
Vicki Einhellig, RPh
President & CEO
August 23, 2021
Hello Community Partners,
We have important updates for your teams~
The Pfizer COVID 19 vaccine is FDA APPROVED. The FDA has granted full approval to the Pfizer COVID-19 Vaccine (Brand name- Comirnaty) for the prevention of COVID-19 disease in individuals 16 years of age and older. The vaccine also continues to be available under emergency use authorization (EUA), including for individuals 12 through 15 years of age and for the administration of a third dose in certain immunocompromised individuals.
Good Day Pharmacy has both Pfizer and Moderna vaccine for residents and staff.
Booster doses:
The US Department of Health and Human Services has announced plans to offer a booster shot for fully vaccinated people starting September 20. However, we are awaiting formal guidance from Federal and State health agencies on the process for administering booster shots. Once we receive that guidance, we will share information with you about how to schedule booster shots. At this time, additional doses for fully vaccinated people are only available to those who are immunocompromised. If the FDA authorizes and ACIP recommends a booster dose, the goal is for the first people eligible for a booster dose to be the first to receive a COVID-19 vaccination (those who are most at risk). This includes healthcare providers, residents of long-term care facilities, and other older adults.
There are two distinct potential uses for an additional dose of COVID-19 vaccine:
- Additional dose after an initial primary vaccine series: an additional dose of vaccine administered when the immune response following a primary vaccine series is likely to be insufficient. An additional mRNA COVID-19 vaccine dose is recommended for moderately to severely immunocompromised people after an initial 2-dose primary mRNA vaccine series.
- Booster dose is an additional vaccine administered when the initial sufficient immune response to a primary vaccine series is likely to have waned over time. The need for and timing of a COVID-19 booster dose has not been established. Therefore, no booster doses are recommended at this time. This guidance will be updated as more information becomes available.
For more information about who might be eligible for an additional dose, visit https://www.cdc.gov/coronavirus/2019-ncov/vaccines/booster-shot.htmlthe
Another important update: CMS issued a statement announcing that, in collaboration with the CDC, the agency is developing an emergency regulation that would apply to all nursing homes participating in Medicare and Medicaid that all staff must be vaccinated against COVID-19. It is unclear how CMS expects to audit or enforce this new mandate, which will apply to over 15,000 nursing homes, but the agency expects guidance to be released sometime in September. CMS strongly encourages nursing home staff to get vaccinated ahead of the release of the guidance. Good Day is actively monitoring and will share details as soon as they become available.
More information will be coming soon! If you have specific COVID-19 questions, please email us at mobrien@gooddaypharmacy.com.
Thank you,
Vicki Einhellig, RPh
President & CEO